Regardless of infection site or patient age, drotrecogin alfa (activated) is associated with a 19.4% reduction in relative risk of death and that survival benefit continues through long-term follow-up, according to results reported here at CHEST 2002, the 68th annual meeting of the American College of Chest Physicians.
A handful of studies presented here underlined previously reported efficacy, but a pair of reports from the PROWESS study appear to confirm the claim that the drug “can work in any population for infection at any site” and that the survival advantage is not a short term finding. PROWESS assessed 28-day survival for patients receiving drotrecogin alfa (activated) plus standard therapy or placebo plus standard therapy.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!